2023 CiteScore: 0.7
pISSN: 0044-6025
eISSN: 1735-9694
Editor-in-Chief:
Ahmadreza Dehpour, PharmD, PhD
This journal is a member of, and subscribes to the principles of, the Committee on Publication Ethics (COPE).
Vol 42, No 5 (2004)
Induction of labor is one of the most common procedures during pregnancy. Various methods for cervical ripening and labor induction have been described in the obstetrics literature; but the role of corticosteroids in the process of labor is not entirely understood. This study challenged the possible role of corticosteroids in induction of labor by extra-amniotic injection through an inflated intracervical Foley balloon catheter. This randomized trial was conducted on 44 women with a single pregnancy, intact membranes, and an unfavorable cervix. They were randomly assigned to receive either 20 mg of dexamethasone in saline solution (study group, n=22) or saline solution only (control group, n=22) administered extra-amniotically through an intracervical inflated Foley balloon catheter. Eighteen (81.8%) patients in the study group and 20 (90.9%) in the control group entered the active phase of labor and were delivered vaginally. The mean time intervals between induction of labor to the active phase and between induction of labor to delivery were significantly shorter in the study group compared with those of the control group (3.3±2.1 hours vs. 9±4.7 hours, P<0.01, 5.7±3.4 hours vs. 6.9±4.7 hours, P<0.01, respectively). There was no maternal or fetal complication in study or control group. The intracervical Foley balloon catheter with extra-amniotic corticosteroids was more efficient in reducing the induction-to-delivery interval for termination of midtrimester pregnancies than the same Foley catheter with saline solution only. Cervical ripening with extra-amniotic corticosteroids possesses the advantages of simplicity, low cost, and lack of systemic or serious side effects.
The 1991 Bethesda System for cervical/vaginal cytology reporting has defined adequacy criteria, including unsatisfactory designation. Most laboratories in USA and a few laboratories in Iran have implemented these criteria, but only few studies about clinical implications have been performed. All unsatisfactory Papanicolaou (Pap) smears taken between August 2000 and March 2002 were retrieved from the file of cytologic reports of Mirza Koochak Khan Hospital's Department of Pathology. Of 4,598 total Pap smears 204 (4.4%) were unsatisfactory (corresponding atypical rate of 2.5% and a SIL/carcinoma rate of 0.97%). About 20.2% of unsatisfactory Pap smears were from patients with a history of epithelial abnormalities. The majority (71 of 204 specimens; 35%) of follow-up Pap smears or biopsies occurred within 6 months,12% within 6-12 months,1% within 12-18 months and 1% after 18 months. Approximately 59% had no follow-up. The first repeat Pap smear or histologic specimen in 83 patients with follow-up was negative in 71 (85%), unsatisfactory in 2(2.4%), epithelial cell abnormality in 11 (13.2%) and atypical squamous cells of undetermined significance in 4(4.8%). Nonmalignant conditions contributing to the unsatisfactory smears on histologic specimens (23%) included cervicitis, endocervical polyp and endometritis. Majority of patients with unsatisfactory Pap smears were followed up within 6 months. A significant number(13.2%) of those with follow-up had eventual diagnosis of epithelial cell abnormality. Benign pathologic conditions also contributed to unsatisfactory smears. These patients were more likely to have a history of abnormalities. Unsatisfactory specimens are associated with benign as well as preneoplastic/neoplastic conditions. Clinical correlation should be the first step in delineating the cause of the unsatisfactory diagnosis.
2023 CiteScore: 0.7
pISSN: 0044-6025
eISSN: 1735-9694
Editor-in-Chief:
Ahmadreza Dehpour, PharmD, PhD
This journal is a member of, and subscribes to the principles of, the Committee on Publication Ethics (COPE).
All the work in this journal are licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |